DE69124590T2 - Glykosaminoglykan gemischt mit phospholipid oder lipid, seine herstellung und krebszellenmetastaseninhibitor - Google Patents

Glykosaminoglykan gemischt mit phospholipid oder lipid, seine herstellung und krebszellenmetastaseninhibitor

Info

Publication number
DE69124590T2
DE69124590T2 DE69124590T DE69124590T DE69124590T2 DE 69124590 T2 DE69124590 T2 DE 69124590T2 DE 69124590 T DE69124590 T DE 69124590T DE 69124590 T DE69124590 T DE 69124590T DE 69124590 T2 DE69124590 T2 DE 69124590T2
Authority
DE
Germany
Prior art keywords
glycosaminoglycan
phospholipid
lipid
derivative
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69124590T
Other languages
English (en)
Other versions
DE69124590D1 (de
Inventor
Katsukiyo Sakurai
Nobuo Sugiura
Koji Kimata
Sakaru Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seikagaku Corp
Original Assignee
Seikagaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2193816A external-priority patent/JP2986518B2/ja
Priority claimed from JP2193817A external-priority patent/JP2997018B2/ja
Priority claimed from JP2193818A external-priority patent/JP2986519B2/ja
Application filed by Seikagaku Corp filed Critical Seikagaku Corp
Application granted granted Critical
Publication of DE69124590D1 publication Critical patent/DE69124590D1/de
Publication of DE69124590T2 publication Critical patent/DE69124590T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
DE69124590T 1990-07-24 1991-07-24 Glykosaminoglykan gemischt mit phospholipid oder lipid, seine herstellung und krebszellenmetastaseninhibitor Expired - Fee Related DE69124590T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2193816A JP2986518B2 (ja) 1990-07-24 1990-07-24 癌転移抑制剤
JP2193817A JP2997018B2 (ja) 1990-07-24 1990-07-24 燐脂質又は脂質結合グリコサミノグリカン
JP2193818A JP2986519B2 (ja) 1990-07-24 1990-07-24 燐脂質結合グリコサミノグリカン
PCT/JP1991/000995 WO1992001720A1 (en) 1990-07-24 1991-07-24 Phospholipid- or lipid-combining glycosaminoglycan, production thereof, and cancer metastasis inhibitor

Publications (2)

Publication Number Publication Date
DE69124590D1 DE69124590D1 (de) 1997-03-20
DE69124590T2 true DE69124590T2 (de) 1997-06-12

Family

ID=27326820

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69124590T Expired - Fee Related DE69124590T2 (de) 1990-07-24 1991-07-24 Glykosaminoglykan gemischt mit phospholipid oder lipid, seine herstellung und krebszellenmetastaseninhibitor

Country Status (10)

Country Link
US (1) US5464942A (de)
EP (1) EP0493622B1 (de)
KR (1) KR0181295B1 (de)
AT (1) ATE148713T1 (de)
AU (1) AU647814B2 (de)
CA (1) CA2067211C (de)
DE (1) DE69124590T2 (de)
FI (1) FI103279B1 (de)
NO (1) NO305368B1 (de)
WO (1) WO1992001720A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3199405B2 (ja) * 1991-08-30 2001-08-20 生化学工業株式会社 肝細胞球状集塊化剤及び球状集塊化肝細胞の製造方法
IT1260137B (it) * 1992-04-17 1996-03-28 Alfa Wassermann Spa Glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 dell'acido alfa-l-iduronico-2-0-solfato
RU2157239C2 (ru) * 1992-07-13 2000-10-10 Юкэрион, Инк. Способ модификации, способ обеспечения связывания белка с антителом, фармацевтические композиции, способ диагностики
JP3714683B2 (ja) * 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
JP2787279B2 (ja) * 1994-05-17 1998-08-13 雪印乳業株式会社 糖リン脂質及びその調製法
US6228998B1 (en) 1994-07-22 2001-05-08 Seikagaku Kogyo Kabushiki Kaisha Amino spacered glycosaminoglycan derivatives and their use in copolymerization with acrylamide
FR2725622A1 (fr) * 1994-10-14 1996-04-19 Fabre Pierre Dermo Cosmetique Ceramide greffee anti-elastase
CA2175282A1 (en) * 1996-04-29 1997-10-30 Rudolf Edgar Falk Use of forms of hyaluronic acid (ha) for the treatment of cancer
AU2602200A (en) * 1999-01-08 2000-07-24 Board Of Trustees Of The University Of Arkansas, The Synthetic, highly charged molecules and uses thereof
JP3032824B1 (ja) * 1999-01-28 2000-04-17 東京医科歯科大学長 骨誘導促進剤
AU6472900A (en) * 1999-08-10 2001-03-13 Seikagaku Corporation Glycosaminoglycan derivatives and utilization thereof
US7101859B2 (en) * 2000-01-10 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7772196B2 (en) * 2000-01-10 2010-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7393938B2 (en) * 2000-01-10 2008-07-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US9040078B2 (en) * 2000-01-10 2015-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases of the nervous system
US7141552B2 (en) * 2000-01-10 2006-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US8501701B2 (en) * 2000-01-10 2013-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
US20090325876A1 (en) * 2004-09-29 2009-12-31 Saul Yedgar Use of lipid conjugates in the treatment of diseases associated with vasculature
US8076312B2 (en) * 2000-01-10 2011-12-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Use of lipid conjugates in the treatment of disease
US8304395B2 (en) * 2000-01-10 2012-11-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Lipid conjugates in the treatment of disease
US20060189571A1 (en) * 2000-01-10 2006-08-24 Saul Yedgar Use of lipid conjugates in the treatment of infection
US7893226B2 (en) 2004-09-29 2011-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Use of lipid conjugates in the treatment of diseases
US8916539B2 (en) * 2000-01-10 2014-12-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
US7811999B2 (en) * 2000-01-10 2010-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Use of lipid conjugates in the treatment of diseases
US7608598B2 (en) 2000-01-10 2009-10-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of conjunctivitis
US7259152B2 (en) 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
US8883761B2 (en) * 2001-01-10 2014-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases associated with vasculature
US20070185052A1 (en) * 2005-08-03 2007-08-09 Saul Yedgar Use of lipid conjugates in cystic fibrosis and applications thereof
US7280612B2 (en) * 2003-07-25 2007-10-09 Zarbana Digital Fund Llc Digital branch calibrator for an RF transmitter
US8137685B2 (en) * 2003-10-29 2012-03-20 Teijin Limited Hyaluronic acid compound, hydrogel thereof and joint treating material
JP4744973B2 (ja) * 2005-08-05 2011-08-10 株式会社トプコン 眼底カメラ
US8475694B2 (en) 2005-10-25 2013-07-02 Zephyros, Inc. Shaped expandable material
US8859524B2 (en) 2005-11-17 2014-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of chronic rhinosinusitis
US8906882B2 (en) 2005-11-17 2014-12-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of allergic rhinitis
US20080183282A1 (en) * 2006-03-09 2008-07-31 Saul Yedgar Use of lipid conjugates for the coating of stents and catheters
AU2007320737B2 (en) * 2006-11-14 2014-04-03 Celsus Therapeutics Plc Contact lens compositions
CA2705785A1 (en) * 2006-11-14 2008-05-22 Saul Yedgar Use of lipid conjugates in the treatment of diseases or disorders of the eye
EP2429532A4 (de) * 2009-05-11 2015-05-27 Yissum Res Dev Co Lipid-polymer-konjugate, ihre herstellung und verwendung
GB0916205D0 (en) 2009-09-15 2009-10-28 Zephyros Inc Improvements in or relating to cavity filling
EP2547342A2 (de) * 2010-03-17 2013-01-23 KTB Tumorforschungsgesellschaft mbH Kombinierte verwendung von phospholipiden und sulfatgruppentragenden polysacchariden zur hemmung von metastasierung
CA2703532C (en) * 2010-05-10 2018-05-01 Eva Turley Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications
MX2021012576A (es) * 2019-04-29 2021-11-12 Bausch & Lomb Red polimerica de glicofosfolipidos y uso de la misma.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2374910A1 (fr) * 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
FR2492259A1 (fr) * 1980-10-21 1982-04-23 Idinvex Sa Formulation d'heparine
US4362737A (en) * 1981-04-13 1982-12-07 Schaefer Rolf Transdermal carrier materials
US4654327A (en) * 1982-04-21 1987-03-31 Research Corp. Quaternary ammonium complexes of heparin
US4604376A (en) * 1982-04-21 1986-08-05 Research Corporation Enteric compounds and complexes
DK168876B1 (da) * 1982-12-20 1994-07-04 Harvard College Middel, der kan administreres oralt eller subcutant, til inhibering af angiogenese hos pattedyr samt fremgangsmåde til fremstilling af et sådant middel
JPS6117A (ja) * 1984-06-11 1986-01-06 Seikagaku Kogyo Co Ltd ムコ多糖系癌転移抑制剤
US5122450A (en) * 1985-10-24 1992-06-16 Research Corporation Limited Biochemical reagent
IL79255A0 (en) * 1986-06-26 1986-09-30 Hadassah Med Org Composition for metastasis prevention
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
WO1989008499A1 (en) * 1988-03-17 1989-09-21 Nippon Fine Chemical Co., Ltd. Liposome
JPH0219393A (ja) * 1988-07-08 1990-01-23 Higeta Shoyu Kk Ｎ‐アセチルガラクトサミノオリゴ糖及びその製造方法
JPH0258501A (ja) * 1988-08-25 1990-02-27 Mitsubishi Gas Chem Co Inc リポ多糖およびその用途
JPH03220201A (ja) * 1988-11-18 1991-09-27 Eisai Co Ltd プロスタグランジン類と多糖類の結合体

Also Published As

Publication number Publication date
WO1992001720A1 (en) 1992-02-06
NO921083L (no) 1992-05-21
EP0493622A1 (de) 1992-07-08
DE69124590D1 (de) 1997-03-20
AU8226691A (en) 1992-02-18
CA2067211A1 (en) 1992-01-25
NO305368B1 (no) 1999-05-18
FI920717A0 (fi) 1992-02-19
EP0493622A4 (en) 1993-10-27
NO921083D0 (no) 1992-03-19
ATE148713T1 (de) 1997-02-15
CA2067211C (en) 2004-06-15
US5464942A (en) 1995-11-07
KR0181295B1 (ko) 1999-04-01
EP0493622B1 (de) 1997-02-05
FI103279B (fi) 1999-05-31
FI103279B1 (fi) 1999-05-31
AU647814B2 (en) 1994-03-31
KR920702377A (ko) 1992-09-03

Similar Documents

Publication Publication Date Title
DE69124590D1 (de) Glykosaminoglykan gemischt mit phospholipid oder lipid, seine herstellung und krebszellenmetastaseninhibitor
PT785938E (pt) Pirrolocarbazoles fundidos
ATE116338T1 (de) Chemisch modifizierte proteine und deren herstellung.
KR830006219A (ko) 아미노산 유도체의 제조방법
ATE54917T1 (de) Physostigminderivate mit acetylcholinesteraseinhibitoreigenschaften, und das entsprechende herstellungsverfahren.
ATE42303T1 (de) Herstellung von nukleosiden.
MY102439A (en) A process for the production of mixtures of c6-c10- fatty acids.
DK375079A (da) 3,4,5-trihydroxypiperidinderivater
SE8404930D0 (sv) Aqueous compositions containing stabilized enzymes
FI801184A (fi) Foerfarande foer framstaellning av imidazolidinderivat
GB1212090A (en) Aliphatic diol-diones
ATE71078T1 (de) Glyzerinderivate.
YU58298A (sh) POSTUPAK ZA PROIZVODNJU ESTARA α-TOKOFEROLA
FI884345A (fi) Sackaridderivat.
UA26443A (uk) Похідhі 20,21-диhоребурhамеhіhу, їх рацемати або оптичhі ізомери, або їх адитивhі солі з оргаhічhими кислотами, що мають hоотропhі та аhтидепресивhі властивості
PT98700A (pt) Processo para a preparacao de acidos aminometanofosfonico e de acidos aminometil-fosfinicos
JPS5488275A (en) Production of 2,2,6,6-tetramethyl-4-oxopiperidine
ATE178993T1 (de) Direkter cholesterolassay
GB1498919A (en) Furanose-o-pyridylcarboxylic acid esters
ES2165533T3 (es) Composicion para la proteccion de celulas vegetales.
KR910012131A (ko) 풀 제조방법
ATE287449T1 (de) Cis-9,10-octadecenoamidase
ES2054651T3 (es) Intermedios y su empleo en la sintesis de compuestos organicos.
JPS5515426A (en) Pyranopyrrole derivative
JPS5356643A (en) Trans-4-aminomethylcyclohexane-carboxylic acid ester

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee